Pharmaceuticals Italy

Italy Dengue Vaccines Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Italy Dengue Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Product, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Italy · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $15.2 Mn Placeholder estimate
Estimate 2025 $18.2 Mn 2.5% of the global market
Projected 2034 $91.0 Mn 400.7% Adds $72.8 Mn over 9 forecast years
CAGR 2025–2034 19.6% Faster than 88% of 180 Pharmaceuticals markets here
Key players 5
  • Italy is 2.52% of the global market.
  • In Europe, the largest is Germany at $25.1 Mn.
  • Fastest growing: Italy (this report) at 19.6% a year.
  • Italy ranks 2nd of 6 by size in Europe.

Market size projection

Italy

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$72.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Dengue Vaccines Market market size by year, Italy
YearMarket sizeChange that yearSince 2025
2024 (estimate) $15.2 Mn — —
2025 (base) $18.2 Mn +$3.0 Mn —
2026 (forecast) $21.7 Mn +$3.6 Mn +19.6%
2027 (forecast) $26.0 Mn +$4.3 Mn +43%
2028 (forecast) $31.1 Mn +$5.1 Mn +71.1%
2029 (forecast) $37.2 Mn +$6.1 Mn +104.6%
2030 (forecast) $44.5 Mn +$7.3 Mn +144.7%
2031 (forecast) $53.2 Mn +$8.7 Mn +192.7%
2032 (forecast) $63.6 Mn +$10.4 Mn +250%
2033 (forecast) $76.1 Mn +$12.5 Mn +318.6%
2034 (forecast) $91.0 Mn +$14.9 Mn +400.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Italy Dengue Vaccines Market Analysis at a glance
Market size, 2025$18.2 Mn placeholder estimate
Forecast, 2034$91.0 Mn placeholder estimate
Growth (CAGR), 2025–203419.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, age and end user (see all)
Key playersTakeda Pharmaceutical Company Ltd, Sanofi, Butantan Institute, Merck & Co., Inc., Panacea Biotec (see all)
Regulator in ItalyAIFASource: Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
Active clinical trials2 in ItalySource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Italy Dengue Vaccines Market Analysis Executive Summary

Dengue vaccines protect against dengue fever, a mosquito-borne disease spreading fast in tropical and warming regions.

Key segments of the dengue Vaccines market include product (Live Attenuated Vaccines and Candidate Vaccines) and age (Children, Adolescents and Adults).

Bar chart: Italy Dengue Vaccines market size, 2024–2034, placeholder estimates. $15.2 Mn in 2024, $18.2 Mn in 2025 and $91.0 Mn in 2034, 19.6% CAGR.
Italy Dengue Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Italy Dengue Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the dengue Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the dengue Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the dengue Vaccines market.

Competitive Landscape for Dengue Vaccines Market in Italy

The dengue Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Dengue Vaccines Market in Italy

Dengue Vaccines in Italy: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement.⁠[1] The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for.⁠[2] ClinicalTrials.gov lists 2 studies on Dengue Vaccines that are recruiting, active or about to start in Italy.⁠[3]

[1] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[2] Italian Ministry of Health. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for dengue Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Italy.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Dengue Vaccines right now, from free public sources.

Clinical trials

2 active trials in Italy

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Takeda Pharmaceutical Company Ltd 5 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Sanofi 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Dengue Vaccines in context

Italy compared

  • Health spending per person: 3,398 US$ per person (2024). World: 1,317 US$ per person (2023). 4th highest of the 6 countries we cover in Europe.[1]
  • Doctors: 4.19 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 4th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 25.1% of people (2025). World: 10.4% of people (2025). Highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Dengue Vaccines market in Italy?
Placeholder estimate: about $18.2 Mn in 2025, rising to about $91.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Dengue Vaccines market in Italy growing?
Placeholder estimate: about 19.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Dengue Vaccines market report cover?
The report splits the market by product (Live Attenuated Vaccines, Candidate Vaccines), age (Children, Adolescents, Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Dengue Vaccines market?
Key players include Takeda Pharmaceutical Company Ltd, Sanofi, Butantan Institute, Merck & Co., Inc. and Panacea Biotec.
What is driving the Dengue Vaccines market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the dengue Vaccines market.
Who regulates Dengue Vaccines in Italy?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement. Source: Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
How is healthcare paid for in Italy?
The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for. Source: Italian Ministry of Health. Checked 14 Nov 2026.
How many clinical trials on Dengue Vaccines are running in Italy?
2 studies are recruiting, active or about to start in Italy, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.
How much research is published on Dengue Vaccines?
PubMed lists 165 papers on Dengue Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Italy

See all

Related on vaccines and infectious diseases

See the topic